Acromegaly

• EMA withdrawal · 2025-03-21
  EMA Withdrawn: Mycapssa (octreotide acetate) — Amryt Pharmaceuticals DAC

  The EMA has withdrawn the marketing authorization for Mycapssa (octreotide acetate) for acromegaly.

• CLINICAL_TRIALS withdrawal · 2025-02-13
  Clinical Trial Update: Oral Glucose Tolerance Testing (OGTT) on Patients Taking Somatostatin Analogs

  This clinical trial update reports the withdrawal of a study evaluating oral glucose tolerance testing in patients treated with somatostatin…

• CLINICAL_TRIALS withdrawal · 2008-10-06
  Clinical Trial Update: Inter-Assay Growth Hormone and IGF-I Variability

  This Clinical Trials entry indicates that the inter-assay variability study for growth hormone and IGF-I in acromegaly and growth hormone de…